Analyst Upgrades

• Bristol-Myers (BMY) to hold from underperform at Jefferies.
• Pep Boys (PBY) to buy from hold at Stifel Nicolaus.
• Tesla Motors (TSLA) to overweight from equal weight at Morgan Stanley.
• Emerson (EMR) to buy from hold at Deutsche Bank.
• ARM Holdings (ARMH) to buy from neutral at BofA/Merrill.
• NetLogic (NETL) and Cavium Networks (CAVM) to buy from hold at Auriga.
• Aimco (AIV) to hold from sell at Citigroup.
• Ceragon Networks (CRNT) to overweight from equal weight at Barclays.

Continue reading Analyst Calls: BMY, CAG, CAVM, CEPH, OPEN, PBY, SOL, TSLA, WDC ...

Analyst Calls: BMY, CAG, CAVM, CEPH, OPEN, PBY, SOL, TSLA, WDC ... originally appeared on BloggingStocks on Thu, 31 Mar 2011 11:30:00 EST. Please see our terms for use of feeds.

"According to the Spectrem Group, which recently polled the country's wealthiest people, they're the most optimistic they've been in months," says Marc Lichtenfeld.

The contributing editor to Investment U explains, "Let's take a look at 3 stocks that millionaires (and aspiring ones) should pay attention to: Apple (AAPL), Bristol-Myers Squibb (BMY) and Varian Medical Systems (VAR).

"And according to Fidelity, 83% of millionaires surveyed said the financial crisis did not shake their confidence in investing. And of those who said they'll invest more money in the stock market, nearly 60% of them plan to buy technology stocks. And just under half expect to acquire pharmaceutical and healthcare stocks.

Continue reading Three Favorite Stocks of Wealthy Investors

Three Favorite Stocks of Wealthy Investors originally appeared on BloggingStocks on Wed, 23 Mar 2011 15:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Aetna (AET) to buy from neutral at Goldman.
• Kellogg (K) to buy from neutral at UBS.
• PetSmart (PETM) to outperform from market perform at JMP Securities.
• NetApp (NTAP) and Scripps Networks (SNI) to buy from hold at Wunderlich.
• Thoratec (THOR) to buy from hold at Auriga.
• ArcelorMittal (MT) to overweight from neutral at HSBC.
• Bristol-Myers (BMY) to outperform from neutral at Cowen.
• Eaton Vance (EV) to neutral from sell at Ticonderoga.
• Adtran (ADTN) to buy from underperform at BofA/Merrill.

Continue reading Analyst Calls: AET, BMY, DVN, GLW, K, MRK, MT, PETM, SPLS, WY ...

Analyst Calls: AET, BMY, DVN, GLW, K, MRK, MT, PETM, SPLS, WY ... originally appeared on BloggingStocks on Mon, 07 Feb 2011 11:40:00 EST. Please see our terms for use of feeds.

Continue reading U.S. Stock Futures Slightly Higher Ahead of Jobless Claims, Earnings

U.S. Stock Futures Slightly Higher Ahead of Jobless Claims, Earnings originally appeared on BloggingStocks on Thu, 27 Jan 2011 08:30:00 EST. Please see our terms for use of feeds.

"Many growth and income investors will eventually need to start taking dividends to supplement other forms of cash flow," says Chuck Carlson, an expert in dividend reinvestment plans.

The editor of the DRIP Investor explains, "And many investors would like to receive those dividends on a regular basis. And, in fact, you can get monthly dividend check from a portfolio holding just three stocks.

Continue reading Monthly Dividends from a 3-Stock Growth Portfolio

Monthly Dividends from a 3-Stock Growth Portfolio originally appeared on BloggingStocks on Mon, 06 Dec 2010 10:30:00 EST. Please see our terms for use of feeds.

The earnings crunch continues this week, and analysts surveyed by Thomson Reuters are anticipating lots of strong quarterly reports.

For example, year-over-year earnings growth from big oil Chevron (CVX), ConocoPhillips (COP), ExxonMobil (XOM) and Royal Dutch Shell (RDS.A) are expected to be in double digits. The same is true of many other energy and mining concerns reporting this week: Allegheny Technologies (ATI), Alliant Energy (LNT), Arch Coal (ACI), Cliffs Natural Resources (CLF), CMS Energy (CMS), CONSOL Energy (CNX), DPL (DPL), Hess Corp. (HES), Minerals Technologies (MTX), Pioneer Natural Resources (PXD), PPL Corp. (PPL), Southwestern Energy (SWN), Total (TOT), Whiting Petroleum (WLL), Williams Companies (WMB) and Wisconsin Energy (WEC).

Continue reading Week in Preview: The Earnings Crunch Rolls On (MSFT, COP, V)

Week in Preview: The Earnings Crunch Rolls On (MSFT, COP, V) originally appeared on BloggingStocks on Sun, 24 Oct 2010 12:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Merriman upgraded Penn National (PENN) to buy from neutral, citing the company's strong balance sheet and management team. The firm also raised its target range for shares to $34 to $37.60.
• BMO Capital upgraded Cooper Companies (COO) to outperform from market perform and raised its price target to $55 from $46. The firm sees upside to Street estimates and increased visibility.
• Argus upgraded Watson Pharma (WPI) to buy from hold based on valuation.
• Phillips-Van Heusen (PVH) was upgraded to conviction buy from neutral at Goldman.
• Allstate (ALL) was upgraded to overweight from neutral at JPMorgan.
• Weingarten Realty (WRI) was upgraded to neutral from underperform at BofA/Merrill.

Continue reading Analyst Calls: AAPL, ALL, AOL, AVP, AZPN, BMY, COO, F, K, MSFT, PENN, UAL ...

Analyst Calls: AAPL, ALL, AOL, AVP, AZPN, BMY, COO, F, K, MSFT, PENN, UAL ... originally appeared on BloggingStocks on Mon, 04 Oct 2010 12:00:00 EST. Please see our terms for use of feeds.

"Foreign corporations have been on a mini buying spree in 2010. Not surprising, merger and acquisition activity has heated up a bit in the drug sector," says Chuck Carlson, editor of The DRIP Investor.

The dividend expert explains, " Global merger and acquisition activity topped $1 trillion in the first half of 2010, a 9.4% increase over the previous year. And Bristol-Myers Squibb (BMY), recommend stock in our Editor's Portfolio, has been one of the more active participants.

Continue reading Bristol-Myers Squibb (BMY): Buying Growth?

Bristol-Myers Squibb (BMY): Buying Growth? originally appeared on BloggingStocks on Wed, 29 Sep 2010 13:00:00 EST. Please see our terms for use of feeds.

Early Friday morning, Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) announced the results of their randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes that is inadequately controlled with metformin therapy. The study showed that dapagliflozin was non-inferior compared to glipizide (sulphonylurea) and improved glycosylated hemoglobin levels (HbA1c).

In addition to these results, the study also showed that dapagliflozin plus metformin brought about "significant reductions in efficacy secondary endpoints: reduction in total body weight from baseline, compared with a weight gain on glipizide plus metformin therapy, and a reduced number of patients reporting one or more hypoglycemic events."

Continue reading Bristol-Myers Squibb and AstraZeneca Report Success in Diabetes Trial

Bristol-Myers Squibb and AstraZeneca Report Success in Diabetes Trial originally appeared on BloggingStocks on Fri, 24 Sep 2010 09:30:00 EST. Please see our terms for use of feeds.

Continue reading Bristol-Myers Squbb Boosted by Blood Thinner Study

Bristol-Myers Squbb Boosted by Blood Thinner Study originally appeared on BloggingStocks on Tue, 31 Aug 2010 13:30:00 EST. Please see our terms for use of feeds.

Continue reading Protective Parents Could Send Mead Johnson Higher

Protective Parents Could Send Mead Johnson Higher originally appeared on BloggingStocks on Mon, 02 Aug 2010 15:30:00 EST. Please see our terms for use of feeds.

"New products are the life-blood of any pharmaceutical company. Unfortunately, blockbuster drug breakthroughs have been fairly rare in recent years, lowering valuations for pharmaceutical stocks," says Chuck Carlson.

The editor of The DRIP Investor, which focuses on dividend reinvestment strategies, explains, "The good news is that the lone drug stock in the Editor's Portfolio, Bristol-Myers Squibb (BMY), has had a spate of good news recently on the drug-development front.

"The company recently announced that a mid-stage trial of an experimental arthritis drug had met its goal, supporting further development of the drug.

Continue reading Bristol-Myers Squibb (BMY): 'Solid, Quality Play'

Bristol-Myers Squibb (BMY): 'Solid, Quality Play' originally appeared on BloggingStocks on Mon, 26 Jul 2010 10:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• FBR Capital upgraded Noble Corporation (NE) to outperform from market perform as it finds the company's acquisition of Frontier Drilling as smart and strategic. The firm upped its target price for shares to $42 from $36.
• Citigroup upgraded Ameriprise (AMP) to buy from hold, citing potential margin expansion from the Columbia acquisition. The firm maintains a $50 price target for shares.
• Thomas Weisel upgraded Jabil Circuit (JBL) to overweight from market weight, citing valuation and the company's growth prospects. The firm raised its target for shares to $20 from $18.
• Blackrock (BLK) was upgraded to outperform from market perform at Keefe Bruyette.
• Disney (DIS) and News Corp (NWS) were upgraded to buy from neutral at Goldman.
• Portland General Electric (POR) was upgraded to neutral from underperform at BofA/Merrill.

Continue reading Analyst Calls: AH, AMP, BDX, DIS, ETH, JBL, MRK, NE, NWS, TWX, VIA ...

Analyst Calls: AH, AMP, BDX, DIS, ETH, JBL, MRK, NE, NWS, TWX, VIA ... originally appeared on BloggingStocks on Tue, 29 Jun 2010 12:00:00 EST. Please see our terms for use of feeds.

Continue reading Wall Street Ignoring Big Pharma -- Should You?

Wall Street Ignoring Big Pharma -- Should You? originally appeared on BloggingStocks on Mon, 28 Jun 2010 14:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Barclays upgraded GlaxoSmithKline (GSK) to overweight from equal weight and said investor concerns regarding Advair and Avandia are overdone.
• Leerink upgraded Bristol-Myers (BMY) to outperform from market perform, citing management's pipeline execution. Shares were also upgraded at Citigroup this morning to buy from hold.
• Goldman upgraded Medco Health (MHS) to buy from neutral and raised its price target on shares to $76 from $67. The firm cites valuation and expectations that earnings will accelerate in 2H10 driven by a stronger generic outlook.
• U.S. Steel (X) was upgraded to neutral from sell at UBS.
• Blyth (BTH) was upgraded to hold from underperform at Jefferies.
• IPC The Hospitalist Co. (IPCM) was upgraded to buy from hold at Deutsche Bank.

Continue reading Analyst Calls: BMY, FSLR, GSK, LGF, MHS, PVH, SAI, SU, WAG, X ...

Analyst Calls: BMY, FSLR, GSK, LGF, MHS, PVH, SAI, SU, WAG, X ... originally appeared on BloggingStocks on Fri, 11 Jun 2010 11:30:00 EST. Please see our terms for use of feeds.

Bristol-Myers Squibb (BMY) broke above a key down-trending resistance level yesterday after the company received positive phase-three trial data for a drug that treats advanced skin cancer.

Bristol-Myers' ipilimumab compound is proving to be an effective treatment for patients with metastatic melanoma -- a disease with few available pharmaceutical treatments.

With the good news from the FDA and the positive breakout, Bristol-Myers is looking like a great buy candidate.

Continue reading Skin Cancer Breakthrough Boosts Bristol-Myers

Skin Cancer Breakthrough Boosts Bristol-Myers originally appeared on BloggingStocks on Tue, 08 Jun 2010 14:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Auriga upgraded Cisco (CSCO) to buy from hold, citing the company's improving strategic position in data centers.
• Blue Nile (NILE) was raised to buy from hold by Citigroup due to the recent pullback in shares.
• DuPont Fabros (DFT) was upgraded to buy from neutral at UBS, which said that said fundamentals in the data center space have been improving.
• Baird upgraded Sterling Bancshares (SBIB) to neutral from underperform based on valuation.
• Goldman Sachs upgraded Bristol-Myers (BMY) to buy from neutral.
• Amazon.com (AMZN) was raised to conviction buy from buy by Goldman.
• Jefferies upgraded Celgene (CELG) to buy from hold.

Continue reading Analyst Calls: AAPL, ABT, AMZN, BMY, CSCO, DNB, EAT, INTU, NILE ...

Analyst Calls: AAPL, ABT, AMZN, BMY, CSCO, DNB, EAT, INTU, NILE ... originally appeared on BloggingStocks on Mon, 07 Jun 2010 11:20:00 EST. Please see our terms for use of feeds.

"Although the new health care legislation means that the pharmaceutical industry will face about $90 billion in new taxes and fees over time, the legislation also brings many benefits to pharmaceutical companies including a potentially huge influx of new customers now able to afford prescription medication through insurance coverage," says Melvin Pasternak.

The editor of Double-Digit Trading explains, "My top stock pick in the pharma sector is Bristol-Myers Squibb (BMY), which I believe offers a very attractive valuation and a great chart."

Continue reading Bristol-Myers Squibb (BMY): Technical and Fundamental Buy

Bristol-Myers Squibb (BMY): Technical and Fundamental Buy originally appeared on BloggingStocks on Fri, 09 Apr 2010 13:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
• JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
• Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
• Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
• Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
• Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.

Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...

Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ... originally appeared on BloggingStocks on Fri, 12 Mar 2010 11:00:00 EST. Please see our terms for use of feeds.

"It's time for income investors to come back to what's historically been a mainstay of diversified portfolios: big pharmaceutical companies. We're adding one of the sector's most durable members to the Income Portfolio, Bristol-Myers Squibb (BMY)," says Roger Conrad.

In Personal Finance newsletter, he explains, "The stock has been a lackluster performer since the 1990s, when it was last a Portfolio recommendation. The company's underlying business, however, has become ever-more valuable.

Continue reading Bristol-Myers Squibb (BMY): Time to Buy Pharma

Bristol-Myers Squibb (BMY): Time to Buy Pharma originally appeared on BloggingStocks on Thu, 25 Feb 2010 11:00:00 EST. Please see our terms for use of feeds.